Rhino-orbital mucormycosis in a Mexican patient with COVID-19: Case report

Versiones

XML
HTML
PDF

Palabras clave

SARS-CoV-2; Invasive fungal infections; PostCOVID-19 mucormycosis

Cómo citar

Gálvez Romeo, J. L. (2023). Rhino-orbital mucormycosis in a Mexican patient with COVID-19: Case report: Rhino-orbital mucormycosis in a Mexican patient with COVID-19: Case report. Revista Alergia México, 69(2), 93–97. https://doi.org/10.29262/ram.v69i2.1185 (Original work published 4 de enero de 2023)
Recibido 2022-11-03
Aceptado 2022-11-16
Publicado 2023-02-07

Resumen

Background: A variety of bacterial and fungal co-infections may be attributed to the coronavirus disease 2019 (COVID-19), particularly in people who already have a medical condition such diabetes mellitus or those who received large dosages of steroids.

Case report: We described a 52-year-old diabetic man who was receiving high doses of dexamethasone and antibiotics while receiving am-bulatory care for COVID-19 pneumonia. His anterior rhinoscopy revealed a necrotic scab, and a sample confirmed Mucor spp. He underwent surgery and was given amphotericin as a result of the severity of the condition, palpebral ptosis, and right ocular palsy he was experiencing. The patien ́s progression was satisfactory.

Conclusions: pre-existing diabetes mellitus, previous steroid and antimicrobial use, as well as SARS-CoV-2 infection are some of the risk factors associated with Mucor spp. infection. Prompt detection of mucormycosis is important in the management of these affected patients

https://doi.org/10.29262/ram.v69i2.1185
XML
HTML
PDF

Citas

Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37(2):e40.

García LAC. Experiencia de mucormicosis en el Hospital Juárez de México. Rev Hosp Juárez México. 2017;71(1):3-13.

Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56(1):29-43.

Quiroz, N., Villanueva, J. del P., & Lozano, E. A. (2017). Mucormycosis. Journal of the Colombian Association of Dermatology and Dermatological Surgery, 25(4), 284–293. https://doi.org/10.29176/2590843X.302

Hernández JL, Buckley CJ. Mucormycosis. En: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 [citado 3 de mayo de 2022]. Disponible en: http://www.ncbi.nlm.nih.gov/books/NBK544364/

Liu M, Spellberg B, Phan QT, Fu Y, Fu Y, Lee AS, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest. 2010;120(6):1914-24.

Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18(3):556-69.

Bonifaz A, Tirado-Sánchez A, Hernández-Medel ML, Araiza J, Kassack JJ, del Angel-Arenas T, et al. Mucormycosis at a tertiary-care center in Mexico. A 35-year retrospective study of 214 cases. Mycoses. 2021;64(4):372-80.

Camps R. The treatment of mucormycosis (zygomycosis) in the 21st century. Rev Iberoam Micol. 2018;35(4):217-21.

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301.

Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SC, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-21.

Creative Commons License

Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.

Derechos de autor 2023 Revista Alergia México

Métricas

Cargando métricas ...